Search

Introduction: Recent studies have suggested a higher incidence of cardiovascular disease (CVD) among patients with chronic kidney disease (CKD) in the USA than in Japan. Hyperphosphatemia, a possible risk for CVD, may explain this difference; however, international differences in phosphate parameters in CKD have not been well elaborated. Methods: By using the baseline data from the USA and the Japanese nation-wide, multicenter, CKD cohort studies; the Chronic Renal Insufficiency Cohort Study (CRIC, N = 3,870) and the Chronic Kidney Disease-Japan Cohort Study (CKD-JAC, N = 2,632), we harmonized the measures and compared clinical parameters regarding phosphate metabolism or serum phosphate, fibroblast growth factor-23 (FGF23), and parathyroid hormone (PTH), in the cross-sectional model. Results: Multivariable linear regression analyses revealed that serum phosphate levels were significantly higher in CRIC across all levels of estimated glomerular filtration rate (eGFR) with the greatest difference being observed at lower levels of eGFR. Serum FGF23 and 25-hydroxy vitamin D (25OHD) levels were higher in CRIC, while PTH levels were higher in CKD-JAC at all levels of eGFR. Adjustments for demographics, 25OHD, medications, dietary intake or urinary excretion of phosphate, PTH, and FGF23 did not eliminate the difference in serum phosphate levels between the cohorts (0.43, 0.46, 0.54, 0.64, and 0.78 mg/dL higher in CRIC within eGFR strata of >50, 41–50, 31–40, 21–30, and ≤20 mL/min/1.73 m2, respectively). These findings were consistent when only Asian CRIC participants (N = 105) were included in the analysis. Conclusion: Serum phosphate levels in CRIC were significantly higher than those of CKD-JAC across all stages of CKD, which may shed light on the international variations in phosphate parameters and thus in cardiovascular risk among CKD patients. The key mechanisms for the substantial differences in phosphate parameters need to be elucidated.

There is growing interest in therapeutic intervention that targets disease-relevant RNAs using small molecules. While there have been some successes in RNA-targeted small-molecule discovery, a deeper understanding of structure–activity relationships in pursuing these targets has remained elusive. One of the best-studied tertiary-structured RNAs is the theophylline aptamer, which binds theophylline with high affinity and selectivity. Although not a drug target, this aptamer has had many applications, especially pertaining to genetic control circuits. Heretofore, no compound has been shown to bind the theophylline aptamer with greater affinity than theophylline itself. However, by carrying out a high-throughput screen of low-molecular-weight compounds, several unique hits were identified that are chemically distinct from theophylline and bind with up to 340-fold greater affinity. Multiple atomic-resolution X-ray crystal structures were determined to investigate the binding mode of theophylline and four of the best hits. These structures reveal both the rigidity of the theophylline aptamer binding pocket and the opportunity for other ligands to bind more tightly in this pocket by forming additional hydrogen-bonding interactions. These results give encouragement that the same approaches to drug discovery that have been applied so successfully to proteins can also be applied to RNAs.

Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the development of a TLR8 antagonist competition assay and its application for hit generation of dual TLR7/8 antagonists are reported. The structure-guided optimization of the pyridone hit 3 using this biochemical assay in combination with cellular and TLR8 cocrystal structural data resulted in the identification of a highly potent and selective TLR7/8 antagonist (27) with in vivo efficacy. The two key steps for optimization were (i) a core morph guided by a TLR7 sequence alignment to achieve a dual TLR7/8 antagonism profile and (ii) introduction of a fluorine in the piperidine ring to reduce its basicity, resulting in attractive oral pharmacokinetic (PK) properties and improved TLR8 binding affinity.

The goal of modern dentistry is to return patients to oral health in a predictable fashion. The partial and complete edentulous patient may be unable to recover normal function, esthetics, comfort, or speech with a traditional removable prosthesis. The patient’s function when wearing a denture may be reduced to one sixth of the level formerly experienced with natural dentition; however, an implant prosthesis may return the function to near-normal limits. The esthetics of the edentulous patient is affected as a result of muscle and bone atrophy. In order to replace a missing tooth, the development of materials science and technology improved the materials for implant application. Nowadays, titanium has become the most popular implant material due to its advantages. The first submerged implant placed by Strock was still functioning 40 years later. Recently, zirconia implants and innovative surface designs are being researched and practiced. In this chapter, these materials will be comparatively discussed through contemporary literature and research.

Background and objectives Endothelial dysfunction is common among patients with CKD. We tested the efficacy and safety of combination treatment with sodium nitrite and isoquercetin on biomarkers of endothelial dysfunction in patients with CKD. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled phase 2 pilot trial enrolled 70 patients with predialysis CKD. Thirty-five were randomly assigned to combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks, and 35 were randomly assigned to placebo. The primary outcome was mean change in flow-mediated vasodilation over the 12-week intervention. Secondary and safety outcomes included biomarkers of endothelial dysfunction, inflammation, and oxidative stress as well as kidney function, methemoglobin, and adverse events. Intention-to-treat analysis was conducted. Results Baseline characteristics, including age, sex, race, cigarette smoking, history of hypertension and diabetes, use of renin-angiotensin system blockers, BP, fasting glucose, lipid profile, kidney function, urine albumin-creatinine ratio, and endothelial biomarkers, were comparable between groups. Over the 12-week intervention, flow-mediated vasodilation increased 1.1% (95% confidence interval, −0.1 to 2.3) in the treatment group and 0.3% (95% confidence interval, −0.9 to 1.5) in the placebo group, and net change was 0.8% (95% confidence interval, −0.9 to 2.5). In addition, changes in biomarkers of endothelial dysfunction (vascular adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, vWf, endostatin, and asymmetric dimethylarginine), inflammation (TNF-α, IL-6, C-reactive protein, IL-1 receptor antagonist, and monocyte chemoattractant protein-1), and oxidative stress (oxidized LDL and nitrotyrosines) were not significantly different between the two groups. Furthermore, changes in eGFR, urine albumin-creatinine ratio, methemoglobin, and adverse events were not significantly different between groups. Conclusions This randomized phase 2 pilot trial suggests that combination treatment with sodium nitrite and isoquercetin did not significantly improve flow-mediated vasodilation or other endothelial function biomarkers but also did not increase adverse events compared with placebo among patients with CKD. Clinical Trial registry name and registration number: Nitrite, Isoquercetin, and Endothelial Dysfunction (NICE), NCT02552888

We present a new parametrization of the d + 3He → p + 4He fusion reaction astrophysical factor based on the effective range approximation, which is an effective theoretical method for describing near-threshold, including resonance, nuclear reactions. In the framework of this approximation we describe experimental data on the energy dependence of the cross section and the astrophysical factor within the experimental uncertainties in the energy range of 0-800 keV. On this basis we calculate the temperature dependence of the Maxwellian-averaged reaction rate in the range of 0-400 keV. In conclusion, we discuss the effect of the calculated reaction rates on the Lawson criterion for thermonuclear reactors based on d-3He fuel.

Purpose To evaluate the rate of graft resorption in autogenous iliac bone grafting (IBG) and guided bone regeneration (GBR) in patients with atrophic maxillae. Materials and Methods We performed a retrospective study involving patients requiring implant placement who underwent IBG or GBR. Volumetric changes of the graft sites were evaluated by imaging studies. The primary predictor and outcome variables were augmentation technique and rate of volumetric resorption, respectively. Secondary outcome variables included bone gain, success of grafting, insertion torque of implants, and requirement for vestibuloplasty. Results The sample comprised 39 patients (21 with GBR and 18 with IBG). One patient in the IBG group had temporary sensory disturbance at the donor site, and one patient in the GBR group had late exposure of the nonresorbable membrane. The average values of percent volume reduction in the GBR and IBG groups were 12.26% ± 2.35% and 35.94% ± 7.94%, respectively, after healing and 15.87% ± 1.99% and 41.62% ± 6.97%, respectively, at last follow-up. The IBG group exhibited a significantly higher reduction in bone volume than the GBR group at both time points ( P = .001). The mean values of horizontal and vertical bone gain after healing in the IBG group were significantly higher than those in the GBR group ( P = .006 and P = .001, respectively). The mean implant torque during implant placement in the GBR group was significantly higher than that in the IBG group ( P = .024). There was no significant difference in the requirement for vestibuloplasty between the two groups ( P > .05). Conclusions Although both hard tissue augmentation approaches provide an adequate volume of bone graft for implant insertion, IBG results in greater graft resorption at maxillary augmented sites than GBR. Clinicians should consider the differences in the extent of graft resorption between the two methods while choosing the treatment approach.

Objective The aim of this study was to evaluate the effect of mineralized plasmatic matrix (MPM), comprising a combination of synthetic graft and platelet concentrates, on bone regeneration. Methods Critical size defects of 6-mm diameter were created on the tibias of 6 male sheep, with the animals subsequently assigned into 2 groups. Of the 5 bone defects generated per animal, 4 were randomly filled with MPM, beta-tricalcium phosphate graft (β-TCP), platelet-rich fibrin (PRF) + β-TCP, and autogenous graft. One defect was left empty as a control group. Animals were killed at 3 weeks (early healing group) and 6 weeks (late healing group). The specimens underwent histologic and histomorphometric analysis to evaluate new bone formation. Results In both healing periods, new bone formation from autogenous bone was observed significantly more often than from biomaterials or the empty defect. The degree of new bone formation for MPM was significantly higher than that of the control group at all healing periods. In addition, it was significantly higher in both healing periods than that of β-TCP albeit only in the late healing period than that of the PRF + β-TCP combination. In all biomaterial groups, residual graft ratios decreased from early to late healing periods. Conclusion The results indicated that MPM, representing growth factors in a fibrin network, increases new bone formation in surgically created defects in sheep tibia as confirmed by histologic assessment.

Purpose To evaluate the morbidity of iliac block bone grafting performed under general anesthesia (GA) or combined spinal epidural anesthesia (CSEA). Materials and Methods We implemented a retrospective study including patients who underwent anterior iliac block bone grafting for deficient maxillary alveolar ridges. The anesthetic technique (GA or CSEA) was the primary predictor variable. The outcome variables were pain, gait disturbance, neurosensory disturbance (0 to 5 weeks), vomiting tendency (0 to 7 days), and postoperative hospitalization period (0 to 2 days). Results The sample comprised 22 patients, with 10 in the GA group and 12 in the CSEA group. No surgical complications except sensory disturbance in 2 patients were observed during the study period. Pain during initial healing (P < .001), the gait disturbance rate at 3 weeks after surgery (P = .003), and the vomiting tendency on the day of surgery (P < .001) were significantly higher in the GA group than in the CSEA group; all variables showed significant improvement with time in both groups. The postoperative hospitalization period was also significantly longer for the GA group than for the CSEA group (P

Background and objectives Masked hypertension and elevated nighttime BP are associated with increased risk of hypertensive target organ damage and adverse cardiovascular and renal outcomes in patients with normal kidney function. The significance of masked hypertension for these risks in patients with CKD is less well defined. The objective of this study was to evaluate the association between masked hypertension and kidney function and markers of cardiovascular target organ damage, and to determine whether this relationship was consistent among those with and without elevated nighttime BP. Design, setting, participants, & measurements This was a cross-sectional study. We performed 24-hour ambulatory BP in 1492 men and women with CKD enrolled in the Chronic Renal Insufficiency Cohort Study. We categorized participants into controlled BP, white-coat, masked, and sustained hypertension on the basis of clinic and 24-hour ambulatory BP. We obtained echocardiograms and measured pulse wave velocity in 1278 and 1394 participants, respectively. Results The percentages of participants with controlled BP, white-coat, masked, and sustained hypertension were 49.3%, 4.1%, 27.8%, and 18.8%, respectively. Compared with controlled BP, masked hypertension independently associated with low eGFR (−3.2 ml/min per 1.73 m2; 95% confidence interval, −5.5 to −0.9), higher proteinuria (+0.9 unit higher in log2 urine protein; 95% confidence interval, 0.7 to 1.1), and higher left ventricular mass index (+2.52 g/m2.7; 95% confidence interval, 0.9 to 4.1), and pulse wave velocity (+0.92 m/s; 95% confidence interval, 0.5 to 1.3). Participants with masked hypertension had lower eGFR only in the presence of elevated nighttime BP (−3.6 ml/min per 1.73 m2; 95% confidence interval, −6.1 to −1.1; versus −1.4 ml/min per 1.73 m2; 95% confidence interval, −6.9 to 4.0, among those with nighttime BP Conclusions Masked hypertension is common in patients with CKD and associated with lower eGFR, proteinuria, and cardiovascular target organ damage. In patients with CKD, ambulatory BP characterizes the relationship between BP and target organ damage better than BP measured in the clinic alone.

Extensive alveolar bone resorption because of pneumatized maxillary sinus is a common problem that limits dental implant placement. Maxillary sinus floor augmentation (MSFA) is an accepted treatment protocol that provides sufficient bone volume. The aim of this study was to evaluate the percentage of graft volume reduction following MSFA using cone beam computed tomography. In this retrospective study, cone beam computed tomography scans of MSFA were measured to evaluate the volume of the grafted sinus with deproteinized bovine bone (DBB), mineralized allograft (MA), or a mixture of MA and demineralized allograft as a composite. The volumetric changes in sinus augmentation between 2 weeks (T-I) and 6 months (T-II) after operation were analyzed. Thirty-nine patients were included in this study. The average percent volume reduction was 8.14 ± 3.76%, 19.38 ± 9.22%, and 24.66 ± 4.68% for DBB, MA, and composite graft, respectively. A significant graft volume reduction was found between T-I and T-II for all groups (P

Purpose. Bone atrophy after tooth loss may leave insufficient bone for implant placement. We compared volumetric changes after autogenous ramus block bone grafting (RBG) or guided bone regeneration (GBR) in horizontally deficient maxilla before implant placement. Materials and Methods. In this retrospective study, volumetric changes at RBG or GBR graft sites were evaluated using cone-beam computed tomography. The primary outcome variable was the volumetric resorption rate. Secondary outcomes were bone gain, graft success, and implant insertion torque. Results. Twenty-four patients (28 grafted sites) were included (GBR, 15; RBG, 13). One patient (RBG) suffered mucosal dehiscence at the recipient site 6 weeks after surgery, which healed spontaneously. Mean volume reduction in the GBR and RBG groups was 12.48 ± 2.67% and 7.20 ± 1.40%, respectively. GBR resulted in significantly more bone resorption than RBG (P<0.001). Mean horizontal bone gain and width after healing were significantly greater in the GBR than in the RBG group (P=0.002 and 0.005, resp.). Implant torque was similar between groups (P>0.05). Conclusions. Both RBG and GBR hard-tissue augmentation techniques provide adequate bone graft volume and stability for implant insertion. However, GBR causes greater resorption at maxillary augmented sites than RBG, which clinicians should consider during treatment planning.

The Joint European Torus (JET) presently operates with the ITER-like wall (ILW) including tungsten divertor. Analyses of the soft X-ray radiation (SXR) data present an important tool for studies of transport of tungsten into JET plasmas. SXR spatial distribution can be measured by horizontal (H) and two vertical (V,T) pinhole cameras. Tomographic reconstruction of SXR emissivity from their data is challenging due to different spectral sensitivities of the cameras which can cause significant inconsistencies due to spectral properties of tungsten radiation. In this contribution an advanced correction based on evaluation of the sensitivity differences for individual lines of view of the SXR detectors is presented. The adjustments take into account atomic data of tungsten as well as the SXR intensity perturbation due to tungsten influx. First results are presented and discussed.

BackgroundPredialysis nephrology care for adults with late stage chronic kidney disease (CKD) is associated with improved outcomes. Less is known about the effects of nephrology care in earlier stages of CKD.ObjectiveWe aimed to evaluate the effect of nephrology care on management of CKD risk factors and complications, CKD progression, incident cardiovascular disease (CVD), and death.DesignThis was a prospective cohort study.ParticipantsParticipants included 3855 men and women aged 21 to 74 years enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study with a mean (SD) estimated glomerular filtration rate (eGFR) at entry of 45 (17) ml/min/1.73 m(2), followed for a median of 6.6 years.Main measuresThe main predictor was self-reported prior contact with a nephrologist at study enrollment. Outcomes evaluated included CKD progression (≥ 50 % eGFR loss or end-stage renal disease), incident CVD, and death.ResultsTwo-thirds (67 %) of the participants reported prior contact with a nephrologist at study enrollment. They were younger, more likely to be male, non-Hispanic white, and had lower eGFR and higher urine protein (p < 0.05). A subgroup with eGFR 30- < 60 ml/min/1.73 m(2) and prior contact with a nephrologist were more likely to receive pharmacologic treatment for CKD-related complications and to report angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEi/ARB) use. After propensity score matching (for reporting prior contact with a nephrologist vs. not) and adjusting for demographic and clinical variables, prior contact with a nephrologist was not significantly associated with CKD progression, incident CVD or death (p > 0.05).ConclusionsOne-third of CRIC participants had not seen a nephrologist before enrollment, and this prior contact was subject to age, sex, and ethnic-related disparities. While prior nephrology care was associated with more frequent treatment of CKD complications and use of ACEi/ARB medications, there was neither an association between this care and achievement of guideline-recommended intermediate measures, nor long-term adverse outcomes.

Studies of hemodialysis patients have shown a U-shaped association between systolic blood pressure (SBP) and mortality. These studies have largely relied on dialysis-unit SBP measures and have not evaluated whether this U-shape also exists in advanced chronic kidney disease, before starting hemodialysis. We determined the association between SBP and mortality at advanced chronic kidney disease and again after initiation of hemodialysis. This was a prospective study of Chronic Renal Insufficiency Cohort participants with advanced chronic kidney disease followed through initiation of hemodialysis. We studied the association between SBP and mortality when participants (1) had an estimated glomerular filtration rate 2 (n=1705), (2) initiated hemodialysis and had dialysis-unit SBP measures (n=403), and (3) initiated hemodialysis and had out-of-dialysis-unit SBP measured at a Chronic Renal Insufficiency Cohort study visit (n=326). Cox models were adjusted for demographics, cardiovascular risk factors, and dialysis parameters. A quadratic term for SBP was included to test for a U-shaped association. At advanced chronic kidney disease, there was no association between SBP and mortality (hazard ratio, 1.02 [95% confidence interval, 0.98–1.07] per every 10 mm Hg increase). Among participants who started hemodialysis, a U-shaped association between dialysis-unit SBP and mortality was observed. In contrast, there was a linear association between out-of-dialysis-unit SBP and mortality (hazard ratio, 1.26 [95% confidence interval, 1.14–1.40] per every 10 mm Hg increase). In conclusion, more efforts should be made to obtain out-of-dialysis-unit SBP, which may merit more consideration as a target for clinical management and in interventional trials.

Introduction. The bone volume of the posterior maxilla may not be appropriate for implant placement, due to factors such as pneumatized maxillary sinus. The purpose of this study was to evaluate the percentage of graft volume reduction following sinus floor elevation (SFE), with either slow resorbable bone substitute only or a composite of slow and fast resorbable bone substitutes, using cone beam computed tomography (CBCT).Materials and Methods. In this retrospective study, CBCT scans of SFE procedures were evaluated to determine the volume of grafted sinus with either deproteinized bovine bone (DBB) or a 2 : 1 mixture of biphasic calcium sulfate (CS) and DBB, as a composite. The volumetric changes of sinus augmentations were measured 2 weeks (V-I) and 6 months (V-II) after operation.Results. Thirty-three patients were included in this study. The average percentage volume reduction was9.39±3.01% and17.65±4.15% for DBB and composite grafts, respectively. A significant graft volume reduction was observed between V-I and V-II for both groups (p<0.01). The DBB group exhibited significantly less volume reduction than the composite group (p<0.01).Conclusions. Augmented sinus volume may change before implant placement. DBB offers greater volume stability during healing than composite grafts.

The photoinduced rearrangement pathways of simple 2,5-dienones and the natural product santonin were found to be effectively rerouted by amines, giving rise to unprecedented products. Either cis olefins or cyclobutenes were obtained from 4,4-disubstituted 2,5-dienone upon irradiation (365 nm) in the presence of various amines depending on the solvent. Previously undescribed [4.4.0] and [5.3.0] fused-ring-containing products were obtained when santonin was irradiated (365 nm) in the presence of methylamine. The amines present in these reactions were incorporated into the products by means of amide-group formation.

The 2014–2016 JET results are reviewed in the light of their significance for optimising the ITER research plan for the active and non-active operation. More than 60 h of plasma operation with ITER first wall materials successfully took place since its installation in 2011. New multi-machine scaling of the type I-ELM divertor energy flux density to ITER is supported by first principle modelling. ITER relevant disruption experiments and first principle modelling are reported with a set of three disruption mitigation valves mimicking the ITER setup. Insights of the L–H power threshold in Deuterium and Hydrogen are given, stressing the importance of the magnetic configurations and the recent measurements of fine-scale structures in the edge radial electric. Dimensionless scans of the core and pedestal confinement provide new information to elucidate the importance of the first wall material on the fusion performance. H-mode plasmas at ITER triangularity (H = 1 at ßN ~ 1.8 and n/nGW ~ 0.6) have been sustained at 2 MA during 5 s. The ITER neutronics codes have been validated on high performance experiments. Prospects for the coming D–T campaign and 14 MeV neutron calibration strategy are reviewed. This work has been carried out within the framework of the EUROfusion Consortium and has received funding from the Euratom research and training programme 2014–2018 under grant agreement No 633053. Peer Reviewed Article signat per 1.173 autors/es: X. Litaudon35, S. Abduallev39, M. Abhangi46, P. Abreu53, M. Afzal7, K.M. Aggarwal29, T. Ahlgren101, J.H. Ahn8, L. Aho-Mantila112, N. Aiba69, M. Airila112, R. Albanese105, V. Aldred7, D. Alegre93, E. Alessi45, P. Aleynikov55, A. Alfier12, A. Alkseev72, M. Allinson7, B. Alper7, E. Alves53, G. Ambrosino105, R. Ambrosino106, L. Amicucci90, V. Amosov88, E. Andersson Sundén22, M. Angelone90, M. Anghel85, C. Angioni62, L. Appel7, C. Appelbee7, P. Arena30, M. Ariola106, H. Arnichand8, S. Arshad41, A. Ash7, N. Ashikawa68, V. Aslanyan64, O. Asunta1, F. Auriemma12, Y. Austin7, L. Avotina103, M.D. Axton7, C. Ayres7, M. Bacharis24, A. Baciero57, D. Baião53, S. Bailey7, A. Baker7, I. Balboa7, M. Balden62, N. Balshaw7, R. Bament7, J.W. Banks7, Y.F. Baranov7, M.A. Barnard7, D. Barnes7, M. Barnes27, R. Barnsley55, A. Baron Wiechec7, L. Barrera Orte34, M. Baruzzo12, V. Basiuk8, M. Bassan55, R. Bastow7, A. Batista53, P. Batistoni90, R. Baughan7, B. Bauvir55, L. Baylor73, B. Bazylev56, J. Beal110, P.S. Beaumont7, M. Beckers39, B. Beckett7, A. Becoulet8, N. Bekris35, M. Beldishevski7, K. Bell7, F. Belli90, M. Bellinger7, É. Belonohy62, N. Ben Ayed7, N.A. Benterman7, H. Bergsåker42, J. Bernardo53, M. Bernert62, M. Berry7, L. Bertalot55, C. Besliu7, M. Beurskens63, B. Bieg61, J. Bielecki47, T. Biewer73, M. Bigi12, P. Bílková50, F. Binda22, A. Bisoffi31, J.P.S. Bizarro53, C. Björkas101, J. Blackburn7, K. Blackman7, T.R. Blackman7, P. Blanchard33, P. Blatchford7, V. Bobkov62, A. Boboc7, G. Bodnár113, O. Bogar18, I. Bolshakova60, T. Bolzonella12, N. Bonanomi97, F. Bonelli56, J. Boom62, J. Booth7, D. Borba35,53, D. Borodin39, I. Borodkina39, A. Botrugno90, C. Bottereau8, P. Boulting7, C. Bourdelle8, M. Bowden7, C. Bower7, C. Bowman110, T. Boyce7, C. Boyd7, H.J. Boyer7, J.M.A. Bradshaw7, V. Braic87, R. Bravanec40, B. Breizman107, S. Bremond8, P.D. Brennan7, S. Breton8, A. Brett7, S. Brezinsek39, M.D.J. Bright7, M. Brix7, W. Broeckx78, M. Brombin12, A. Brosławski65, D.P.D. Brown7, M. Brown7, E. Bruno55, J. Bucalossi8, J. Buch46, J. Buchanan7, M.A. Buckley7, R. Budny76, H. Bufferand8, M. Bulman7, N. Bulmer7, P. Bunting7, P. Buratti90, A. Burckhart62, A. Buscarino30, A. Busse7, N.K. Butler7, I. Bykov42, J. Byrne7, P. Cahyna50, G. Calabrò90, I. Calvo57, Y. Camenen4, P. Camp7, D.C. Campling7, J. Cane7, B. Cannas17, A.J. Capel7, P.J. Card7, A. Cardinali90, P. Carman7, M. Carr7, D. Carralero62, L. Carraro12, B.B. Carvalho53, I. Carvalho53, P. Carvalho53, F.J. Casson7, C. Castaldo90, N. Catarino53, J. Caumont7, F. Causa90, R. Cavazzana12, K. Cave-Ayland7, M. Cavinato12, M. Cecconello22, S. Ceccuzzi90, E. Cecil76, A. Cenedese12, R. Cesario90, C.D. Challis7, M. Chandler7, D. Chandra46, C.S. Chang76, A. Chankin62, I.T. Chapman7, S.C. Chapman28, M. Chernyshova49, G. Chitarin12, G. Ciraolo8, D. Ciric7, J. Citrin38, F. Clairet8, E. Clark7, M. Clark7, R. Clarkson7, D. Clatworthy7, C. Clements7, M. Cleverly7, J.P. Coad7, P.A. Coates7, A. Cobalt7, V. Coccorese105, V. Cocilovo90, S. Coda33, R. Coelho53, J.W. Coenen39, I. Coffey29, L. Colas8, S. Collins7, D. Conka103, S. Conroy22, N. Conway7, D. Coombs7, D. Cooper7, S.R. Cooper7, C. Corradino30, Y. Corre8, G. Corrigan7, S. Cortes53, D. Coster62, A.S. Couchman7, M.P. Cox7, T. Craciunescu86, S. Cramp7, R. Craven7, F. Crisanti90, G. Croci97, D. Croft7, K. Crombé15, R. Crowe7, N. Cruz53, G. Cseh113, A. Cufar81, A. Cullen7, M. Curuia85, A. Czarnecka49, H. Dabirikhah7, P. Dalgliesh7, S. Dalley7, J. Dankowski47, D. Darrow76, O. Davies7, W. Davis55,76, C. Day56, I.E. Day7, M. De Bock55, A. de Castro57, E. de la Cal57, E. de la Luna57, G. De Masi12, J. L. de Pablos57, G. De Temmerman55, G. De Tommasi105, P. de Vries55, K. Deakin7, J. Deane7, F. Degli Agostini12, R. Dejarnac50, E. Delabie73, N. den Harder38, R.O. Dendy7, J. Denis8, P. Denner39, S. Devaux62,104, P. Devynck8, F. Di Maio55, A. Di Siena62, C. Di Troia90, P. Dinca86, R. D’Inca62, B. Ding51, T. Dittmar39, H. Doerk62, R.P. Doerner9, T. Donné34, S.E. Dorling7, S. Dormido-Canto93, S. Doswon7, D. Douai8, P.T. Doyle7, A. Drenik62,81, P. Drewelow63, P. Drews39, Ph. Duckworth55, R. Dumont8, P. Dumortier58, D. Dunai113, M. Dunne62, I. Ďuran50, F. Durodié58, P. Dutta46, B. P. Duval33, R. Dux62, K. Dylst78, N. Dzysiuk22, P.V. Edappala46, J. Edmond7, A.M. Edwards7, J. Edwards7, Th. Eich62, A. Ekedahl8, R. El-Jorf7, C.G. Elsmore7, M. Enachescu84, G. Ericsson22, F. Eriksson16, J. Eriksson22, L.G. Eriksson36, B. Esposito90, S. Esquembri94, H.G. Esser39, D. Esteve8, B. Evans7, G.E. Evans7, G. Evison7, G.D. Ewart7, D. Fagan7, M. Faitsch62, D. Falie86, A. Fanni17, A. Fasoli33, J. M. Faustin33, N. Fawlk7, L. Fazendeiro53, N. Fedorczak8, R.C. Felton7, K. Fenton7, A. Fernades53, H. Fernandes53, J. Ferreira53, J.A. Fessey7, O. Février8, O. Ficker50, A. Field7, S. Fietz62, A. Figueiredo53, J. Figueiredo53,35, A. Fil8, P. Finburg7, M. Firdaouss8, U. Fischer56, L. Fittill7, M. Fitzgerald7, D. Flammini90, J. Flanagan7, C. Fleming7, K. Flinders7, N. Fonnesu90, J. M. Fontdecaba57, A. Formisano79, L. Forsythe7, L. Fortuna30, E. Fortuna-Zalesna19, M. Fortune7, S. Foster7, T. Franke34, T. Franklin7, M. Frasca30, L. Frassinetti42, M. Freisinger39, R. Fresa98, D. Frigione90, V. Fuchs50, D. Fuller35, S. Futatani6, J. Fyvie7, K. Gál34,62, D. Galassi2, K. Gałązka49, J. Galdon-Quiroga92, J. Gallagher7, D. Gallart6, R. Galvão10, X. Gao51, Y. Gao39, J. Garcia8, A. Garcia-Carrasco42, M. García-Muñoz92, J.-L. Gardarein3, L. Garzotti7, P. Gaudio95, E. Gauthier8, D.F. Gear7, S.J. Gee7, B. Geiger62, M. Gelfusa95, S. Gerasimov7, G. Gervasini45, M. Gethins7, Z. Ghani7, M. Ghate46, M. Gherendi86, J.C. Giacalone8, L. Giacomelli45, C.S. Gibson7, T. Giegerich56, C. Gil8, L. Gil53, S. Gilligan7, D. Gin54, E. Giovannozzi90, J.B. Girardo8, C. Giroud7, G. Giruzzi8, S. Glöggler62, J. Godwin7, J. Goff7, P. Gohil43, V. Goloborod’ko102, R. Gomes53, B. Gonçalves53, M. Goniche8, M. Goodliffe7, A. Goodyear7, G. Gorini97, M. Gosk65, R. Goulding76, A. Goussarov78, R. Gowland7, B. Graham7, M.E. Graham7, J. P. Graves33, N. Grazier7, P. Grazier7, N.R. Green7, H. Greuner62, B. Grierson76, F.S. Griph7, C. Grisolia8, D. Grist7, M. Groth1, R. Grove73, C.N. Grundy7, J. Grzonka19, D. Guard7, C. Guérard34, C. Guillemaut8,53, R. Guirlet8, C. Gurl7, H.H. Utoh69, L.J. Hackett7, S. Hacquin8,35, A. Hagar7, R. Hager76, A. Hakola112, M. Halitovs103, S.J. Hall7, S.P. Hallworth Cook7, C. Hamlyn-Harris7, K. Hammond7, C. Harrington7, J. Harrison7, D. Harting7, F. Hasenbeck39, Y. Hatano108, D.R. Hatch107, T.D.V. Haupt7, J. Hawes7, N.C. Hawkes7, J. Hawkins7, P. Hawkins7, P.W. Haydon7, N. Hayter7, S. Hazel7, P.J.L. Heesterman7, K. Heinola101, C. Hellesen22, T. Hellsten42, W. Helou8, O.N. Hemming7, T.C. Hender7, M. Henderson55, S.S. Henderson21, R. Henriques53, D. Hepple7, G. Hermon7, P. Hertout8, C. Hidalgo57, E.G. Highcock27, M. Hill7, J. Hillairet8, J. Hillesheim7, D. Hillis73, K. Hizanidis70, A. Hjalmarsson22, J. Hobirk62, E. Hodille8, C.H.A. Hogben7, G.M.D. Hogeweij38, A. Hollingsworth7, S. Hollis7, D.A. Homfray7, J. Horáček50, G. Hornung15, A.R. Horton7, L.D. Horton36, L. Horvath110, S.P. Hotchin7, M.R. Hough7, P.J. Howarth7, A. Hubbard64, A. Huber39, V. Huber39, T.M. Huddleston7, M. Hughes7, G.T.A. Huijsmans55, C.L. Hunter7, P. Huynh8, A.M. Hynes7, D. Iglesias7, N. Imazawa69, F. Imbeaux8, M. Imríšek50, M. Incelli109, P. Innocente12, M. Irishkin8, I. Ivanova-Stanik49, S. Jachmich58,35, A.S. Jacobsen83, P. Jacquet7, J. Jansons103, A. Jardin8, A. Järvinen1, F. Jaulmes38, S. Jednoróg49, I. Jenkins7, C. Jeong20, I. Jepu86, E. Joffrin8, R. Johnson7, T. Johnson42, Jane Johnston7, L. Joita7, G. Jones7, T.T.C. Jones7, K.K. Hoshino69, A. Kallenbach62, K. Kamiya69, J. Kaniewski7, A. Kantor7, A. Kappatou62, J. Karhunen1, D. Karkinsky7, I. Karnowska7, M. Kaufman73, G. Kaveney7, Y. Kazakov58, V. Kazantzidis70, D.L. Keeling7, T. Keenan7, J. Keep7, M. Kempenaars7, C. Kennedy7, D. Kenny7, J. Kent7, O.N. Kent7, E. Khilkevich54, H.T. Kim35, H.S. Kim80, A. Kinch7, C. king7, D. King7, R.F. King7, D.J. Kinna7, V. Kiptily7, A. Kirk7, K. Kirov7, A. Kirschner39, G. Kizane103, C. Klepper73, A. Klix56, P. Knight7, S.J. Knipe7, S. Knott96, T. Kobuchi69, F. Köchl111, G. Kocsis113, I. Kodeli81, L. Kogan7, D. Kogut8, S. Koivuranta112, Y. Kominis70, M. Köppen39, B. Kos81, T. Koskela1, H.R. Koslowski39, M. Koubiti4, M. Kovari7, E. Kowalska-Strzęciwilk49, A. Krasilnikov88, V. Krasilnikov88, N. Krawczyk49, M. Kresina8, K. Krieger62, A. Krivska58, U. Kruezi7, I. Książek48, A. Kukushkin72, A. Kundu46, T. Kurki-Suonio1, S. Kwak20, R. Kwiatkowski65, O.J. Kwon13, L. Laguardia45, A. Lahtinen101, A. Laing7, N. Lam7, H.T. Lambertz39, C. Lane7, P.T. Lang62, S. Lanthaler33, J. Lapins103, A. Lasa101, J.R. Last7, E. Łaszyńska49, R. Lawless7, A. Lawson7, K.D. Lawson7, A. Lazaros70, E. Lazzaro45, J. Leddy110, S. Lee66, X. Lefebvre7, H.J. Leggate32, J. Lehmann7, M. Lehnen55, D. Leichtle41, P. Leichuer7, F. Leipold55,83, I. Lengar81, M. Lennholm36, E. Lerche58, A. Lescinskis103, S. Lesnoj7, E. Letellier7, M. Leyland110, W. Leysen78, L. Li39, Y. Liang39, J. Likonen112, J. Linke39, Ch. Linsmeier39, B. Lipschultz110, G. Liu55, Y. Liu51, V.P. Lo Schiavo105, T. Loarer8, A. Loarte55, R.C. Lobel7, B. Lomanowski1, P.J. Lomas7, J. Lönnroth1,35, J. M. López94, J. López-Razola57, R. Lorenzini12, U. Losada57, J.J. Lovell7, A.B. Loving7, C. Lowry36, T. Luce43, R.M.A. Lucock7, A. Lukin74, C. Luna5, M. Lungaroni95, C.P. Lungu86, M. Lungu86, A. Lunniss110, I. Lupelli7, A. Lyssoivan58, N. Macdonald7, P. Macheta7, K. Maczewa7, B. Magesh46, P. Maget8, C. Maggi7, H. Maier62, J. Mailloux7, T. Makkonen1, R. Makwana46, A. Malaquias53, A. Malizia95, P. Manas4, A. Manning7, M.E. Manso53, P. Mantica45, M. Mantsinen6, A. Manzanares91, Ph. Maquet55, Y. Marandet4, N. Marcenko88, C. Marchetto45, O. Marchuk39, M. Marinelli95, M. Marinucci90, T. Markovič50, D. Marocco90, L. Marot26, C.A. Marren7, R. Marshal7, A. Martin7, Y. Martin33, A. Martín de Aguilera57, F.J. Martínez93, J. R. Martín-Solís14, Y. Martynova39, S. Maruyama55, A. Masiello12, M. Maslov7, S. Matejcik18, M. Mattei79, G.F. Matthews7, F. Maviglia11, M. Mayer62, M.L. Mayoral34, T. May-Smith7, D. Mazon8, C. Mazzotta90, R. McAdams7, P.J. McCarthy96, K.G. McClements7, O. McCormack12, P.A. McCullen7, D. McDonald34, S. McIntosh7, R. McKean7, J. McKehon7, R.C. Meadows7, A. Meakins7, F. Medina57, M. Medland7, S. Medley7, S. Meigh7, A.G. Meigs7, G. Meisl62, S. Meitner73, L. Meneses53, S. Menmuir7,42, K. Mergia71, I.R. Merrigan7, Ph. Mertens39, S. Meshchaninov88, A. Messiaen58, H. Meyer7, S. Mianowski65, R. Michling55, D. Middleton-Gear7, J. Miettunen1, F. Militello7, E. Militello-Asp7, G. Miloshevsky77, F. Mink62, S. Minucci105, Y. Miyoshi69, J. Mlynář50, D. Molina8, I. Monakhov7, M. Moneti109, R. Mooney7, S. Moradi37, S. Mordijck43, L. Moreira7, R. Moreno57, F. Moro90, A.W. Morris7, J. Morris7, L. Moser26, S. Mosher73, D. Moulton7,1, A. Murari12,35, A. Muraro45, S. Murphy7, N.N. Asakura69, Y.S. Na80, F. Nabais53, R. Naish7, T. Nakano69, E. Nardon8, V. Naulin83, M.F.F. Nave53, I. Nedzelski53, G. Nemtsev88, F. Nespoli33, A. Neto41, R. Neu62, V.S. Neverov72, M. Newman7, K.J. Nicholls7, T. Nicolas33, A.H. Nielsen83, P. Nielsen12, E. Nilsson8, D. Nishijima99, C. Noble7, M. Nocente97, D. Nodwell7, K. Nordlund101, H. Nordman16, R. Nouailletas8, I. Nunes53, M. Oberkofler62, T. Odupitan7, M.T. Ogawa69, T. O’Gorman7, M. Okabayashi76, R. Olney7, O. Omolayo7, M. O’Mullane21, J. Ongena58, F. Orsitto11, J. Orszagh18, B.I. Oswuigwe7, R. Otin7, A. Owen7, R. Paccagnella12, N. Pace7, D. Pacella90, L.W. Packer7, A. Page7, E. Pajuste103, S. Palazzo30, S. Pamela7, S. Panja46, P. Papp18, R. Paprok50, V. Parail7, M. Park66, F. Parra Diaz27, M. Parsons73, R. Pasqualotto12, A. Patel7, S. Pathak46, D. Paton7, H. Patten33, A. Pau17, E. Pawelec48, C. Paz Soldan43, A. Peackoc36, I.J. Pearson7, S.-P. Pehkonen112, E. Peluso95, C. Penot55, A. Pereira57, R. Pereira53, P.P. Pereira Puglia7, C. Perez von Thun35,39, S. Peruzzo12, S. Peschanyi56, M. Peterka50, P. Petersson42, G. Petravich113, A. Petre84, N. Petrella7, V. Petržilka50, Y. Peysson8, D. Pfefferlé33, V. Philipps39, M. Pillon90, G. Pintsuk39, P. Piovesan12, A. Pires dos Reis52, L. Piron7, A. Pironti105, F. Pisano17, R. Pitts55, F. Pizzo79, V. Plyusnin53, N. Pomaro12, O.G. Pompilian86, P.J. Pool7, S. Popovichev7, M.T. Porfiri90, C. Porosnicu86, M. Porton7, G. Possnert22, S. Potzel62, T. Powell7, J. Pozzi7, V. Prajapati46, R. Prakash46, G. Prestopino95, D. Price7, M. Price7, R. Price7, P. Prior7, R. Proudfoot7, G. Pucella90, P. Puglia52, M.E. Puiatti12, D. Pulley7, K. Purahoo7, Th. Pütterich62, E. Rachlew25, M. Rack39, R. Ragona58, M.S.J. Rainford7, A. Rakha6, G. Ramogida90, S. Ranjan46, C.J. Rapson62, J.J. Rasmussen83, K. Rathod46, G. Rattá57, S. Ratynskaia82, G. Ravera90, C. Rayner7, M. Rebai97, D. Reece7, A. Reed7, D. Réfy113, B. Regan7, J. Regaña34, M. Reich62, N. Reid7, F. Reimold39, M. Reinhart34, M. Reinke110,73, D. Reiser39, D. Rendell7, C. Reux8, S.D.A. Reyes Cortes53, S. Reynolds7, V. Riccardo7, N. Richardson7, K. Riddle7, D. Rigamonti97, F.G. Rimini7, J. Risner73, M. Riva90, C. Roach7, R.J. Robins7, S.A. Robinson7, T. Robinson7, D.W. Robson7, R. Roccella55, R. Rodionov88, P. Rodrigues53, J. Rodriguez7, V. Rohde62, F. Romanelli90, M. Romanelli7, S. Romanelli7, J. Romazanov39, S. Rowe7, M. Rubel42, G. Rubinacci105, G. Rubino12, L. Ruchko52, M. Ruiz94, C. Ruset86, J. Rzadkiewicz65, S. Saarelma7, R. Sabot8, E. Safi101, P. Sagar7, G. Saibene41, F. Saint-Laurent8, M. Salewski83, A. Salmi112, R. Salmon7, F. Salzedas53, D. Samaddar7, U. Samm39, D. Sandiford7, P. Santa46, M.I.K. Santala1, B. Santos53, A. Santucci90, F. Sartori41, R. Sartori41, O. Sauter33, R. Scannell7, T. Schlummer39, K. Schmid62, V. Schmidt12, S. Schmuck7, M. Schneider8, K. Schöpf102, D. Schwörer32, S.D. Scott76, G. Sergienko39, M. Sertoli62, A. Shabbir15, S.E. Sharapov7, A. Shaw7, R. Shaw7, H. Sheikh7, A. Shepherd7, A. Shevelev54, A. Shumack38, G. Sias17, M. Sibbald7, B. Sieglin62, S. Silburn7, A. Silva53, C. Silva53, P.A. Simmons7, J. Simpson7, J. Simpson-Hutchinson7, A. Sinha46, S.K. Sipilä1, A.C.C. Sips36, P. Sirén112, A. Sirinelli55, H. Sjöstrand22, M. Skiba22, R. Skilton7, K. Slabkowska49, B. Slade7, N. Smith7, P.G. Smith7, R. Smith7, T.J. Smith7, M. Smithies110, L. Snoj81, S. Soare85, E. R. Solano35,57, A. Somers32, C. Sommariva8, P. Sonato12, A. Sopplesa12, J. Sousa53, C. Sozzi45, S. Spagnolo12, T. Spelzini7, F. Spineanu86, G. Stables7, I. Stamatelatos71, M.F. Stamp7, P. Staniec7, G. Stankūnas59, C. Stan-Sion84, M.J. Stead7, E. Stefanikova42, I. Stepanov58, A.V. Stephen7, M. Stephen46, A. Stevens7, B.D. Stevens7, J. Strachan76, P. Strand16, H.R. Strauss44, P. Ström42, G. Stubbs7, W. Studholme7, F. Subba75, H.P. Summers21, J. Svensson63, Ł. Świderski65, T. Szabolics113, M. Szawlowski49, G. Szepesi7, T.T. Suzuki69, B. Tál113, T. Tala112, A.R. Talbot7, S. Talebzadeh95, C. Taliercio12, P. Tamain8, C. Tame7, W. Tang76, M. Tardocchi45, L. Taroni12, D. Taylor7, K.A. Taylor7, D. Tegnered16, G. Telesca15, N. Teplova54, D. Terranova12, D. Testa33, E. Tholerus42, J. Thomas7, J.D. Thomas7, P. Thomas55, A. Thompson7, C.-A. Thompson7, V.K. Thompson7, L. Thorne7, A. Thornton7, A.S. Thrysøe83, P.A. Tigwell7, N. Tipton7, I. Tiseanu86, H. Tojo69, M. Tokitani67, P. Tolias82, M. Tomeš50, P. Tonner7, M. Towndrow7, P. Trimble7, M. Tripsky58, M. Tsalas38, P. Tsavalas71, D. Tskhakaya jun102, I. Turner7, M.M. Turner32, M. Turnyanskiy34, G. Tvalashvili7, S.G.J. Tyrrell7, A. Uccello45, Z. Ul-Abidin7, J. Uljanovs1, D. Ulyatt7, H. Urano69, I. Uytdenhouwen78, A.P. Vadgama7, D. Valcarcel7, M. Valentinuzzi8, M. Valisa12, P. Vallejos Olivares42, M. Valovic7, M. Van De Mortel7, D. Van Eester58, W. Van Renterghem78, G.J. van Rooij38, J. Varje1, S. Varoutis56, S. Vartanian8, K. Vasava46, T. Vasilopoulou71, J. Vega57, G. Verdoolaege58, R. Verhoeven7, C. Verona95, G. Verona Rinati95, E. Veshchev55, N. Vianello45, J. Vicente53, E. Viezzer62,92, S. Villari90, F. Villone100, P. Vincenzi12, I. Vinyar74, B. Viola90, A. Vitins103, Z. Vizvary7, M. Vlad86, I. Voitsekhovitch34, P. Vondráček50, N. Vora7, T. Vu8, W.W. Pires de Sa52, B. Wakeling7, C.W.F. Waldon7, N. Walkden7, M. Walker7, R. Walker7, M. Walsh55, E. Wang39, N. Wang39, S. Warder7, R.J. Warren7, J. Waterhouse7, N.W. Watkins28, C. Watts55, T. Wauters58, A. Weckmann42, J. Weiland23, H. Weisen33, M. Weiszflog22, C. Wellstood7, A.T. West7, M.R. Wheatley7, S. Whetham7, A.M. Whitehead7, B.D. Whitehead7, A.M. Widdowson7, S. Wiesen39, J. Wilkinson7, J. Williams7, M. Williams7, A.R. Wilson7, D.J. Wilson7, H.R. Wilson110, J. Wilson7, M. Wischmeier62, G. Withenshaw7, A. Withycombe7, D.M. Witts7, D. Wood7, R. Wood7, C. Woodley7, S. Wray7, J. Wright7, J.C. Wright64, J. Wu89, S. Wukitch64, A. Wynn110, T. Xu7, D. Yadikin16, W. Yanling39, L. Yao89, V. Yavorskij102, M.G. Yoo80, C. Young7, D. Young7, I.D. Young7, R. Young7, J. Zacks7, R. Zagorski49, F.S. Zaitsev18, R. Zanino75, A. Zarins103, K.D. Zastrow7, M. Zerbini90, W. Zhang62, Y. Zhou42, E. Zilli12, V. Zoita86, S. Zoletnik113, I. Zychor65 and JET Contributorsa // EUROfusion Consortium JET, Culham Science Centre, Abingdon, OX14 3DB, United Kingdom / 1 Aalto University, PO Box 14100, FIN-00076 Aalto, Finland / 2 Aix Marseille Université, CNRS, Centrale Marseille, M2P2 UMR 7340, 13451, Marseille, France / 3 Aix-Marseille Université, CNRS, IUSTI UMR 7343, 13013 Marseille, France / 4 Aix-Marseille Université, CNRS, PIIM, UMR 7345, 13013 Marseille, France / 5 Arizona State University, Tempe, AZ, United States of America / 6 Barcelona Supercomputing Center, Barcelona, Spain / 7 CCFE, Culham Science Centre, Abingdon, Oxon, OX14 3DB, United Kingdom / 8 CEA, IRFM, F-13108 Saint Paul Lez Durance, France / 9 Center for Energy Research, University of California at San Diego, La Jolla, CA 92093, United States of America / 10 Centro Brasileiro de Pesquisas Fisicas, Rua Xavier Sigaud, 160, Rio de Janeiro CEP 22290-180, Brazil / 11 Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 12 Consorzio RFX, corso Stati Uniti 4, 35127 Padova, Italy / 13 Daegu University, Jillyang, Gyeongsan, Gyeongbuk 712-174, Republic of Korea / 14 Departamento de Física, Universidad Carlos III de Madrid, 28911 Leganés, Madrid, Spain / 15 Department of Applied Physics UG (Ghent University) St-Pietersnieuwstraat 41 B-9000 Ghent, Belgium / 16 Department of Earth and Space Sciences, Chalmers University of Technology, SE-41296 Gothenburg, Sweden / 17 Department of Electrical and Electronic Engineering, University of Cagliari, Piazza d’Armi 09123, Cagliari, Italy / 18 Department of Experimental Physics, Faculty of Mathematics, Physics and Informatics Comenius University Mlynska dolina F2, 84248 Bratislava, Slovakia / 19 Department of Materials Science, Warsaw University of Technology, PL-01-152 Warsaw, Poland / 20 Department of Nuclear and Quantum Engineering, KAIST, Daejeon 34141, Korea / 21 Department of Physics and Applied Physics, University of Strathclyde, Glasgow, G4 ONG, United Kingdom / 22 Department of Physics and Astronomy, Uppsala University, SE-75120 Uppsala, Sweden / 23 Department of Physics, Chalmers University of Technology, SE-41296 Gothenburg, Sweden / 24 Department of Physics, Imperial College London, London, SW7 2AZ, United Kingdom / 25 Department of Physics, SCI, KTH, SE-10691 Stockholm, Sweden / 26 Department of Physics, University of Basel, Basel, Switzerland / 27 Department of Physics, University of Oxford, Oxford, OX1 2JD, United Kingdom / 28 Department of Physics, University of Warwick, Coventry, CV4 7AL, United Kingdom / 29 Department of Pure and Applied Physics, Queens University, Belfast, BT7 1NN, United Kingdom / 30 Dipartimento di Ingegneria Elettrica Elettronica e Informatica, Università degli Studi di Catania, 95125 Catania, Italy / 31 Dipartimento di Ingegneria Industriale, University of Trento, Trento, Italy / 32 Dublin City University (DCU), Dublin, Ireland / 33 Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Plasma Center (SPC), CH-1015 Lausanne, Switzerland / 34 EUROfusion Programme Management Unit, Boltzmannstr. 2, 85748 Garching, Germany / 35 EUROfusion Programme Management Unit, Culham Science Centre, Culham, OX14 3DB, United Kingdom / 36 European Commission, B-1049 Brussels, Belgium / 37 Fluid and Plasma Dynamics, ULB—Campus Plaine—CP 231 Boulevard du Triomphe, 1050 Bruxelles, Belgium / 38 FOM Institute DIFFER, Eindhoven, Netherlands / 39 Forschungszentrum Jülich GmbH, Institut für Energie- und Klimaforschung—Plasmaphysik, 52425 Jülich, Germany / 40 Fourth State Research, 503 Lockhart Dr, Austin, TX, United States of America / 41 Fusion for Energy Joint Undertaking, Josep Pl. 2, Torres Diagonal Litoral B3, 08019, Barcelona, Spain / 42 Fusion Plasma Physics, EES, KTH, SE-10044 Stockholm, Sweden / 43 General Atomics, PO Box 85608, San Diego, CA 92186-5608, United States of America / 44 HRS Fusion, West Orange, NJ, United States of America / 45 IFP-CNR, via R. Cozzi 53, 20125 Milano, Italy / 46 Institute for Plasma Research, Bhat, Gandhinagar-382 428, Gujarat State, India / 47 Institute of Nuclear Physics, Radzikowskiego 152, 31-342 Kraków, Poland / 48 Institute of Physics, Opole University, Oleska 48, 45-052 Opole, Poland / 49 Institute of Plasma Physics and Laser Microfusion, Hery 23, 01-497 Warsaw, Poland / 50 Institute of Plasma Physics AS CR, Za Slovankou 1782/3, 182 00 Praha 8, Czechia / 51 Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, People’s Republic of China / 52 Instituto de Física, Universidade de São Paulo, Rua do Matão Travessa R Nr.187 CEP 05508-090 Cidade Universitária, São Paulo, Brasil / 53 Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal / 54 Ioffe Physico-Technical Institute, 26 Politekhnicheskaya, St Petersburg 194021, Russian Federation / 55 ITER Organization, Route de Vinon, CS 90 046, 13067 Saint Paul Lez Durance, France / 56 Karlsruhe Institute of Technology, PO Box 3640, D-76021 Karlsruhe, Germany / 57 Laboratorio Nacional de Fusión, CIEMAT, Madrid, Spain / 58 Laboratory for Plasma Physics Koninklijke Militaire School—Ecole Royale Militaire, Renaissancelaan 30 Avenue de la Renaissance B-1000, Brussels, Belgium / 59 Lithuanian energy institute, Breslaujos g. 3, LT-44403, Kaunas, Lithuania / 60 Magnetic Sensor Laboratory, Lviv Polytechnic National University, Lviv, Ukraine / 61 Maritime University of Szczecin, Waly Chrobrego 1-2, 70-500 Szczecin, Poland / 62 Max-Planck-Institut für Plasmaphysik, D-85748 Garching, Germany / 63 Max-Planck-Institut für Plasmaphysik, Teilinsitut Greifswald, D-17491 Greifswald, Germany / 64 MIT Plasma Science and Fusion Centre, Cambridge, MA 02139, United States of America / 65 National Centre for Nuclear Research (NCBJ), 05-400 Otwock-Świerk, Poland / 66 National Fusion Research Institute (NFRI), 169-148 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Republic of Korea / 67 National Institute for Fusion Science, Oroshi, Toki, Gifu 509-5292, Japan / 68 National Institute for Fusion Science, Toki, 509-5292, Japan / 69 National Institutes for Quantum and Radiological Science and Technology, Naka, Ibaraki 311-0193, Japan / 70 National Technical University of Athens, Iroon Politechniou 9, 157 73 Zografou, Athens, Greece / 71 NCSR ‘Demokritos’, 153 10, Agia Paraskevi Attikis, Greece / 72 NRC Kurchatov Institute, 1 Kurchatov Square, Moscow 123182, Russian Federation / 73 Oak Ridge National Laboratory, Oak Ridge, TN 37831-6169, United States of America / 74 PELIN LLC, 27a, Gzhatskaya Ulitsa, Saint Petersburg, 195220, Russian Federation / 75 Politecnico di Torino, Corso Duca degli Abruzzi 24, I-10129 Torino, Italy / 76 Princeton Plasma Physics Laboratory, James Forrestal Campus, Princeton, NJ 08543, United States of America / 77 Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, United States of America / 78 SCK-CEN, Nuclear Research Centre, 2400 Mol, Belgium / 79 Second University of Napoli, Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 80 Seoul National University, Shilim-Dong, Gwanak-Gu, Republic of Korea / 81 Slovenian Fusion Association (SFA), Jozef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia / 82 Space and Plasma Physics, EES, KTH SE-100 44 Stockholm, Sweden / 83 Technical University of Denmark, Department of Physics, Bldg 309, DK-2800 Kgs Lyngby, Denmark / 84 The ‘Horia Hulubei’ National Institute for Physics and Nuclear Engineering, Magurele-Bucharest, Romania / 85 The National Institute for Cryogenics and Isotopic Technology, Ramnicu Valcea, Romania / 86 The National Institute for Laser, Plasma and Radiation Physics, Magurele-Bucharest, Romania / 87 The National Institute for Optoelectronics, Magurele-Bucharest, Romania / 88 Troitsk Insitute of Innovating and Thermonuclear Research (TRINITI), Troitsk 142190, Moscow Region, Russian Federation / 89 University of Electronic Science and Technology of China, Chengdu, People’s Republic of China / 90 Unità Tecnica Fusione, ENEA C. R. Frascati, via E. Fermi 45, 00044 Frascati (Roma), Italy / 91 Universidad Complutense de Madrid, Madrid, Spain / 92 Universidad de Sevilla, Sevilla, Spain / 93 Universidad Nacional de Educación a Distancia, Madrid, Spain / 94 Universidad Politécnica de Madrid, Grupo I2A2, Madrid, Spain / 95 Università di Roma Tor Vergata, Via del Politecnico 1, Roma, Italy / 96 University College Cork (UCC), Ireland / 97 University Milano-Bicocca, piazza della Scienza 3, 20126 Milano, Italy / 98 University of Basilicata, Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 99 University of California, 1111 Franklin St., Oakland, CA 94607, United States of America / 100 University of Cassino, Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 101 University of Helsinki, PO Box 43, FI-00014 University of Helsinki, Finland / 102 University of Innsbruck, Fusion@Österreichische Akademie der Wissenschaften (ÖAW), Innsbruck, Austria / 103 University of Latvia, 19 Raina Blvd., Riga, LV 1586, Latvia / 104 University of Lorraine, CNRS, UMR7198, YIJL, Nancy, France / 105 University of Napoli ‘Federico II’, Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 106 University of Napoli Parthenope, Consorzio CREATE, Via Claudio 21, 80125 Napoli, Italy / 107 University of Texas at Austin, Institute for Fusion Studies, Austin, TX 78712, United States of America / 108 University of Toyama, Toyama, 930-8555, Japan / 109 University of Tuscia, DEIM, Via del Paradiso 47, 01100 Viterbo, Italy / 110 University of York, Heslington, York YO10 5DD, United Kingdom / 111 Vienna University of Technology, Fusion@Österreichische Akademie der Wissenschaften (ÖAW), Austria / 112 VTT Technical Research Centre of Finland, PO Box 1000, FIN-02044 VTT, Finland / 113 Wigner Research Centre for Physics, PO Box 49, H-1525 Budapest, Hungary

Purpose: To measure and compare the retentive strength of cements specifically formulated for luting restorations onto implant abutments and to investigate the effect of varying cement gap on retention strength of implant-supported crowns. Materials and methods: Standard titanium abutments were scanned by means of a 3D digital laser scanner. One hundred and sixty standard metal copings were designed by a Computer Aided Design/Computer Aided Manufacturing (CAD/CAM) system with two cement gap values (20 and 40 μm). The copings were cemented to the abutments using the following eight cements with one being the control, zinc oxide temporary cement, while the other seven were specifically formulated implant cements (n = 10): Premier Implant Cement, ImProv, Multilink Implant, EsTemp Implant, Cem-Implant, ImplaTemp, MIS Crown Set, and TempBond NE. The specimens were placed in 100% humidity for 24 hours, and subjected to a pull-out test using a universal testing machine at a 0.5 mm/min crosshead speed. The test results were analyzed with two-way ANOVA, one-way ANOVA, post hoc Tamhane' s T2, and student's t-tests at a significance level of 0.05. Results: Statistical analysis revealed significant differences in retention strength across the cement groups (p 0.05). Conclusions: Resin cements specifically formulated for implant-supported restorations demonstrated significant differences in retention strength. The ranking of cements presented in the study is meant to be an arbitrary guide for the clinician in deciding the appropriate cement selection for CAD/CAM-fabricated metal copings onto implant abutments with different luting space settings.

Purpose. To compare marginal bone loss between subgingivally placed short-collar implants with machined collars and those with machined and laser-microtextured collars.Materials and Methods. The investigators used a retrospective study design and included patients who needed missing posterior teeth replaced with implants. Short-collar implants with identical geometries were divided into two groups: an M group, machined collar; and an L group, machined and laser-microtextured collar. Implants were evaluated according to marginal bone loss, implant success, and probing depth (PD) at 3 years of follow-up.Results. Sixty-two patients received 103 implants (56 in the M group and 47 in the L group). The cumulative survival rate was 100%. All implants showed clinically acceptable marginal bone loss, although bone resorption was lower in the L group (0.49 mm) than in the M group (1.38 mm) at 3 years (p<0.01). A significantly shallower PD was found for the implants in the L group during follow-up (p<0.01).Conclusions. Our results suggest predictable outcomes with regard to bone loss for both groups; however, bone resorption was less in the L group than in the M group before and after loading. The laser-microtextured collar implant may provide a shallower PD than the machined collar implant.

Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular disease (CVD) compared with the general population. Prior studies have produced contradictory results on the association of dietary sodium intake with risk of CVD, and this relationship has not been investigated in patients with CKD.To evaluate the association between urinary sodium excretion and clinical CVD events among patients with CKD.A prospective cohort study of patients with CKD from 7 locations in the United States enrolled in the Chronic Renal Insufficiency Cohort Study and followed up from May 2003 to March 2013.The cumulative mean of urinary sodium excretion from three 24-hour urinary measurements and calibrated to sex-specific mean 24-hour urinary creatinine excretion.A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarction. Events were reported every 6 months and confirmed by medical record adjudication.Among 3757 participants (mean age, 58 years; 45% women), 804 composite CVD events (575 heart failure, 305 myocardial infarction, and 148 stroke) occurred during a median 6.8 years of follow-up. From lowest (2894 mg/24 hours) to highest (≥4548 mg/24 hours) quartile of calibrated sodium excretion, 174, 159, 198, and 273 composite CVD events occurred, and the cumulative incidence was 18.4%, 16.5%, 20.6%, and 29.8% at median follow-up. In addition, the cumulative incidence of CVD events in the highest quartile of calibrated sodium excretion compared with the lowest was 23.2% vs 13.3% for heart failure, 10.9% vs 7.8% for myocardial infarction, and 6.4% vs 2.7% for stroke at median follow-up. Hazard ratios of the highest quartile compared with the lowest quartile were 1.36 (95% CI, 1.09-1.70; P = .007) for composite CVD events, 1.34 (95% CI, 1.03-1.74; P = .03) for heart failure, and 1.81 (95% CI, 1.08-3.02; P = .02) for stroke after multivariable adjustment. Restricted cubic spline analyses of the association between sodium excretion and composite CVD provided no evidence of a nonlinear association (P = .11) and indicated a significant linear association (P .001).Among patients with CKD, higher urinary sodium excretion was associated with increased risk of CVD.

Mandibular third molars are the most common impacted teeth. Mandibular first and second molars do not share the same frequency of occurrence. In rare cases the occlusal surfaces of impacted molars are united by the same follicular space and the roots pointing in opposite direction; these are called kissing molars. In some cases, a supernumerary fourth molar can be seen as unerupted and, in this case, such a supernumerary, deeply impacted fourth molar is seen neighboring kissing molars. The extraction of deeply impacted wisdom molars from the mandible may necessitate excessive bone removal and it causes complications such as damage to the inferior alveolar nerve and iatrogenic fractures of the mandible. This case report describes the use of the sagittal split osteotomy technique to avoid extensive bone removal and protect the inferior alveolar nerve during surgical extruction of multiple impacted teeth.

WOS: 000376992200102 PubMed ID: 27092911 Efficacy of recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB) delivered via absorbable collagen sponge (ACS) on bone formation was evaluated in guinea pig tibias. Three-millimeter-circular bone tibia defects were created in 24 guinea pigs assigned randomly to 4 groups according to the following defect filling materials: ACS only, rhBMP-2_ACS, rhPDGF-BB_ACS, or empty. New bone formation was evaluated histologically and histomorphometrically at 15 (early healing) and 45 days (late healing). Mean new bone per total defect area ratio was 0.73, 0.57, 0.43, and 0.42 in rhBMP-2_ACS, rhPDGF-BB_ACS, ACS only, and empty groups at early healing, respectively. During early healing, significantly more new bone formation was observed in rhBMP-2_ACS and rhPDGF-BB_ACS groups than in the control groups. New bone formation was significantly higher with rhBMP-2_ACS than with rhPDGF-BB_ACS. Mean new bone per total defect area ratio was 0.81, 0.86, 0.74, and 0.75 in the rhBMP2_ACS, rhPDGF-BB_ACS, ACS only, and empty groups at late healing, respectively. During late healing, new bone formation was significantly higher in the rhPDGF-BB_ACS group relative to both control groups, but the results did not differ significantly from those in the rhBMP-2_ACS group. New bone formation in the rhBMP2_ACS group did not change significantly between the healing periods. In the rhPDGF-BB_ACS group, however, new bone formation was significantly higher in the late healing period. Both growth factors accelerated new bone formation in the early healing period. Although rhBMP-2 was more effective in the early healing period, the effects of rhPDGF-BB were longer lasting. Scientific Research Projects Coordination Unit of Istanbul University [2013-10] This study was supported by the Scientific Research Projects Coordination Unit of Istanbul University (Project 2013-10).

Purpose: The aim of this study was to evaluate the stability during healing and before loading of implants placed at two different supracrestal levels according to their collar texture. Materials and Methods: This retrospective study included patients who received posterior implants with the same macro design. Implants with a machined collar were placed 0.3 mm above the crestal bone (M group), while those with a laser-microtextured collar were placed 1 mm above the crestal bone (L group). All implants healed in a single stage with healing abutments. Implant stability quotient (ISQ) values were determined using resonance frequency analysis immediately after implant placement during surgery and after 1, 4, 8, and 12 weeks after surgery. Other evaluated factors for stability included the implant diameter and length and the site of placement (maxilla or mandible). Results: In total, 103 implants (47 L, 56 M) were evaluated. The median ISQ values at baseline and 1 week after placement were significantly higher for the M group than for the L group (p=0.006 and p=0.031, respectively). There were no differences at the subsequent observation points. The ISQ value was higher for wide-diameter than regular diameter (p=0.001) and mandibular implants than maxillary implants (p=0.001 at 0-8. weeks; p=0.012 at 12 weeks) at all observation points. When diameter data were neglected, the implant length did not influence the ISQ value at all observation points. Conclusion: Our results suggest that submerging implant more inside bone may only influence primary stability. Moreover, the implant diameter and site of placement influence primary and secondary stability before loading, whereas the implant length does not when its diameter is not accounted for.

We compare the outcomes of induction therapies with either methylprednisolone (group 1, n = 58), basiliximab (group 2, n = 56) or alemtuzumab (group 3, n = 98) in primary deceased donor kidney transplants with delayed graft function (DGF). Protocol biopsies were performed. Maintenance was tacrolimus and mycophenolate with steroid (group 1 and 2) or without steroid (group 3). One-year biopsy-confirmed acute rejection (AR) rates were 27.6, 19.6 and 10.2 % in group 1, 2 and 3 (p = 0.007). AR was significantly lower in group 3 (p = 0.002) and group 2 (p = 0.03) than in group 1. One-year graft survival rates were 90, 96 and 100 % in group 1, 2 and 3 (log rank p = 0.006). Group 1 had inferior graft survival than group 2 (p = 0.03) and group 3 (p = 0.002). The patient survival rates were not different (96.6, 98.2 and 100 %, log rank p = 0.81). Multivariable analysis using methylprednisolone induction as control indicated that alemtuzumab (OR 0.31, 95 % CI 0.11–0.82; p = 0.03) and basiliximab (OR 0.60, 95 % CI 0.23–0.98; p = 0.018) were associated with lower risk of AR. Therefore, alemtuzumab or basiliximab induction decreases AR and improves graft survival than methylprednisolone alone in patients with DGF. Alemtuzumab induction might also allow patients with DGF to be maintained with contemporary steroid-withdrawal protocol.

Mandibular third molars are the most common impacted teeth. Mandibular first and second molars do not share the same frequency of occurrence. In rare cases the occlusal surfaces of impacted molars are united by the same follicular space and the roots pointing in opposite direction; these are called kissing molars. In some cases, a supernumerary fourth molar can be seen as unerupted and, in this case, such a supernumerary, deeply impacted fourth molar is seen neighboring kissing molars. The extraction of deeply impacted wisdom molars from the mandible may necessitate excessive bone removal and it causes complications such as damage to the inferior alveolar nerve and iatrogenic fractures of the mandible. This case report describes the use of the sagittal split osteotomy technique to avoid extensive bone removal and protect the inferior alveolar nerve during surgical extruction of multiple impacted teeth.

We employ Malliavin calculus techniques to compute the Delta of European type options in the presence of stochastic volatility. We obtain a general formula for the Malliavin weight and apply the derived formula to the well known models of Stein-Stein and Heston in order to show the numerical accuracy and efficiency of our approach.

On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.

Accurate estimation of the glomerular filtration rate (GFR) in patients with preeclampsia requires the collection of a 24-hour urine and can have important therapeutic and diagnostic implications. This procedure is often difficult or impossible to accomplish in this patient group. In this study, the Cockcroft-Gault, the Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas were evaluated for their accuracy in determining GFR in the setting of preeclampsia. The estimated GFRs calculated from the above formulas were compared with the creatinine clearance values obtained from a 24-hour urine collections in 543 preeclamptic patients recruited from several large hospitals. Additionally, a set of new equations, preeclampsia GFR (PGFR), based on ethnicity, was created. The Cockcroft-Gault, MDRD, and CKD-EPI formulas were inaccurate in predicting GFR and both were significantly less accurate than PGFR. The latter formula provided an estimated GFR that was much closer to the creatinine clearance. Current GFR estimation equations based on serum creatinine values in nonpregnant patients are not reliable measures of renal function in patients with preeclampsia. The use of a new formula (PGFR) is recommended.

Background Hemodialysis patients experience a high degree of psychosocial impairment. Methods The psychosocial status of hemodialysis patients after Hurricane Katrina was evaluated using the Hurricane Coping Self-Efficacy (HCSE) measure, the Short Form-12 Health Survey (physical component summary [PCS] and mental component summary [MCS]), and the Center for Epidemiologic Studies Short Depression Scale (CES-D). These scales were administered to 391 hemodialysis patients (86% participation rate), 7 to 14months after Hurricane Katrina. Results The mean score (standard deviation) was 36.2 (9.6) for the HCSE scale, 37.1 (10.9) and 46.7 (12.7) for the PCS and MCS, respectively, and 10.0 (6.5) on the CES-D. Symptoms of depression (CES-D scores ≥10) were present in 45.5% of patients. After age, race, and gender adjustment, evacuating less than 2days before Hurricane Katrina making landfall and more fear of dying were associated with less favorable scores on the HCSE, MCS, and CES-D scales. Patients placed in a shelter and with a longer displacement had significantly lower MCS scores and more depressive symptoms. More depressive symptoms were observed among patients hospitalized in the month after the storm. Those who evacuated to a hotel, with more fear of dying and who were hospitalized in the month after Hurricane Katrina had lower scores on the PCS. Conclusions Impaired psychosocial status was common among dialysis patients surviving Hurricane Katrina and associated with reduced coping. These data demonstrate the need for screening and management of psychosocial issues in hemodialysis patients after disasters.

This chapter reviews multichannel broadband measurement of the soft-X-ray radiation and total radiation in magnetically confined fusion plasma experiments. Common detector types used (including bolometers), details of their application, and interpretation of their measurements are described. An introduction is given to the application of computed tomography methods in the mathematical reconstruction of emission profiles from multiple (approximately) line-integral measurements, taking into account the specific circumstances common in magnetically confined fusion plasma experiments. Although the emphasis is on two-dimensional tomography of poloidal cross sections, the applications of Abel inversion, three-dimensional tomography, vector tomography, and other specific methods are briefly discussed. Several examples of the application and the plasma parameters that can be derived are given.

Background Patients with end-stage renal disease reliant on maintenance hemodialysis therapy may be particularly susceptible to developing post-traumatic stress disorder (PTSD) after natural disasters. Study Design Cross-sectional study. Setting & Participants Patients who received treatment at 9 New Orleans, LA, metropolitan area hemodialysis units before Hurricane Katrina made landfall on August 29, 2005, were recruited for the study. Overall, 391 patients completed the interview between April and October 2006 (participation rate, 85.6%). Predictors Demographic, dialysis-related, and evacuation characteristics. Outcomes & Measurements PTSD was assessed by using the 17-item PTSD Checklist and defined using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria. Results Overall, 23.8% of hemodialysis patients reported symptoms consistent with PTSD. After adjustment for age and sex, black patients were 1.92 (95% confidence interval, 1.31 to 2.83) times more likely than whites to have PTSD. After age, race, and sex adjustment, PTSD was more common in hemodialysis patients who were in their first 2 years of treatment, were evacuated fewer than 2 days before the hurricane made landfall, were evacuated initially to a shelter, and missed 3 or more dialysis treatments because of Hurricane Katrina and its aftermath. Additionally, patients who remained displaced for 3 or more months were more likely to have PTSD. Limitations Data were not available to distinguish between the presence of acute, chronic, or delayed-onset PTSD. Conclusions A substantial proportion of hemodialysis patients had PTSD symptoms approximately 1 year after Hurricane Katrina. Emergency planning for hemodialysis patients should include the identification and treatment of PTSD after future disasters.

Accurate estimation of the glomerular filtration rate (GFR) in patients with preeclampsia is often difficult or impossible to accomplish. In this study, the Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and MDRD2 formulas were evaluated for their accuracy in determining GFR in the setting of preeclampsia. The estimated GFR calculated from these formulas was compared with the creatinine clearance values obtained from a 24-hour urine collection in 209 preeclamptic patients recruited from five large hospitals. Additionally, a set of new equations that more accurately estimate GFR in preeclamptic patients based on ethnicity, preeclampsia GFR (PGFR), was created. Both the CG and MDRD formulas were inaccurate in predicting GFR in preeclamptic patients, and both were significantly less accurate than PGFR. In conclusion, current GFR estimation equations based on serum creatinine values in nonpregnant patients are not reliable measures of renal function in patients with preeclampsia. The use of a new (PGFR) formula is recommended.

The detection of Alfven cascades is of great importance for the development of advanced plasma scenarios with reversed magnetic shear on the JET tokamak, since they allow the determination of the minimum of the safety factor and provide valuable information on the modes that may redistribute fast ions via resonant interaction. X-mode reflectometry is particularly powerful for this diagnosis since the time-frequency evolution, the mode amplitude and the radial localization of these Alfven eigenmodes (AEs) can be simultaneously obtained. This paper reports on the first successful localized measurements of AEs achieved with the recently upgraded X-mode reflectometry diagnostic on JET.

Introduction: Patients with chronic kidney disease (CKD) are at an increased risk of CVD compared to the general population. Left ventricular hypertrophy (LVH) is an independent risk factor for CVD in the general population and in CKD patients. In the general population, sodium (Na) excretion is directly associated with LVH. However, this association has not been examined in patients with CKD. Hypothesis: We hypothesized that in CKD patients, urinary Na excretion would be directly and urinary potassium (K) would be indirectly associated with development of ejection fraction (EF) < 50% and LVH and longitudinal changes in EF and left ventricular mass index (LVMI). Methods: The Chronic Renal Insufficiency Cohort Study (CRIC) is a prospective cohort study of 3,939 participants with CKD. Dietary Na and K excretion were assessed by averaging three 24-hour urinary measures (over 2 years) and calibrated to sex-specific mean 24-hour urinary creatinine excretion. Echocardiograms (ECHO) were conducted at follow-up years 1, 4, and 7 and centrally analyzed to quantify EF and LVMI. LVH is defined as LVMI ≥ 47 g/m 2.7 in women and LVMI ≥ 50 g/m 2.7 in men. Log-linear binomial and linear mixed effects models were used. Results: During follow-up, 676 participants developed EF 196.2 mmol/24 hours) had a relative risk of 1.31 (95% CI 1.08, 1.59) of developing an EF < 50% during follow-up compared to those in the lowest quartile ( Conclusions: Higher Na excretion is associated with a greater likelihood of developing an EF

An investigation of pellet pacing and triggering of Edge Localized Modes (ELMs) was carried out in the frame of ELM mitigation studies aimed at reducing their damaging effects on the plasma-facing components (PFCs). The divertor power load footprint of triggered ELMs was compared with gas puffing controlled ELMs. Small pellets, corresponding to a few per cent of the target plasma particle inventory, were used to minimize the fueling effect and the total particle throughput. There is no evidence that pellets can reduce the divertor power load with respect to gas fueling when operating at the same ELM frequency. The line average density and the energy confinement time remained constant when the gas was progressively substituted by pellets. The launch from the Vertical High Field Side (VHFS) confirmed to be more efficient in ELM triggering than from the Low Field Side (LFS) while the power load footprint remained the same both in time evolution and in spatial distribution when changing the injection geometry. © 2015 Elsevier B.V.